## Edgar Filing: MADDEN DAVID - Form 4

MADDENIDAVU

Form 4										
June 25, 201	14								PPROVAL	
	Washington, D.C. 20549						N OMB Number:	3235-0287		
Check th if no long subject to Section 1 Form 4 o Form 5	F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Section 16(a) of the Securities Exchange Act of 1934,					Estimated burden hoi response	Expires:     January 31 2009       Estimated average       burden hours per       response     0.9			
obligatio may cont <i>See</i> Instru 1(b).	ns Section 170	(a) of the l	Public U	tility Hol	ding Cor		of 1935 or Secti			
(Print or Type I	Responses)									
1. Name and Address of Reporting Person <u>*</u> MADDEN DAVID			2. Issuer Name <b>and</b> Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
			Dicerna Pharmaceuticals Inc [DRNA]							
	. , , ,			of Earliest T Day/Year) 2018	ransaction		X Director Officer (giv below)		% Owner her (specify	
				4. If Amendment, Date Original Filed(Month/Day/Year)			<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>			
(City)	(State)	(Zip)				~	Person			
				le I - Non-I 3.			Acquired, Disposed		-	
1.Title of Security (Instr. 3)	2. Transaction Date 2A. Deem (Month/Day/Year) Execution any (Month/D		Date, if TransactionAcquired (A) or Code Disposed of (D) ay/Year) (Instr. 8) (Instr. 3, 4 and 5) (A)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code V	Amount	or (D) Price	(Instr. 3 and 4)			
Reminder: Rep	ort on a separate line	e for each cl	ass of sec	urities benef	ficially ow	ned directly	or indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

## Edgar Filing: MADDEN DAVID - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	y TransactionDerivative Code Securities		Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 L S (,
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Director Stock Option (right to buy)	\$ 13.08	06/21/2018		А	33,000	<u>(1)</u>	06/21/2028	Common Stock	33,000	

## **Reporting Owners**

Reporting Owner Name / Address		Relationships					
		Director	10% Owner	Officer	Other		
MADDEN DAVID C/O DICERNA PHARMACEUTICAL 87 CAMBRIDGEPARK DRIVE CAMBRIDGE, MA 02140	.S, INC.	X					
Signatures							
/s/ John B. Green, attorney-in-fact	06/25/201	18					
**Signature of Reporting Person	Date						

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This option vests monthly over 12 months from June 21, 2018 ("Grant Date") in substantially equal monthly installments, provided that
(1) the option will vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through each such date or, if earlier, such annual meeting.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.